Vita Life Sciences Ltd
ASX:VLS

Watchlist Manager
Vita Life Sciences Ltd Logo
Vita Life Sciences Ltd
ASX:VLS
Watchlist
Price: 2.17 AUD -1.81%
Market Cap: 119.4m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one VLS stock under the Base Case scenario is 2.22 AUD. Compared to the current market price of 2.17 AUD, Vita Life Sciences Ltd is Undervalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLS Relative Value
Base Case
2.22 AUD
Undervaluation 2%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
30
vs Industry
64
Median 3Y
1.4
Median 5Y
1.4
Industry
2.7
More Details
14
P/E
P/E
Price to Earnings
14
vs History
9
vs Industry
35
Median 3Y
12.1
Median 5Y
11.9
Industry
22.2
More Details
19.9
P/OCF
P/OCF
Price to OCF
19.9
vs History
25
vs Industry
25
Median 3Y
16.7
Median 5Y
12.9
Industry
17.2
More Details
21.1
P/FCFE
P/FCFE
Price to FCFE
21.1
vs History
31
vs Industry
22
Median 3Y
17.7
Median 5Y
14.2
Industry
23.7
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
50
vs Industry
37
Median 3Y
2.4
Median 5Y
2.4
Industry
2.3
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
34
vs Industry
71
Median 3Y
1.1
Median 5Y
1.1
Industry
2.8
More Details
2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2
vs History
36
vs Industry
74
Median 3Y
1.9
Median 5Y
1.8
Industry
5.6
More Details
7.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.9
vs History
22
vs Industry
42
Median 3Y
7
Median 5Y
6.6
Industry
13.3
More Details
7.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.9
vs History
22
vs Industry
44
Median 3Y
7
Median 5Y
6.6
Industry
16.5
More Details
15.3
EV/OCF
EV/OCF
Enterprise Value to OCF
15.3
vs History
26
vs Industry
32
Median 3Y
12.1
Median 5Y
10.4
Industry
15.6
More Details
15.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
15.8
vs History
26
vs Industry
28
Median 3Y
12.5
Median 5Y
10.7
Industry
17.9
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
41
vs Industry
29
Median 3Y
3
Median 5Y
2.7
Industry
2
More Details

Multiples Across Competitors

VLS Competitors Multiples
Vita Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Vita Life Sciences Ltd
ASX:VLS
122.7m AUD 1.5 14 7.9 7.9
US
Eli Lilly and Co
NYSE:LLY
672.1B USD 12.6 48.7 28.9 31.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
430.4B USD 4.7 19 14.5 19
CH
Roche Holding AG
SIX:ROG
208.8B CHF 3.5 25.2 9.5 11.1
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 4.4 30.2 113.6 169.9
CH
Novartis AG
SIX:NOVN
199.1B CHF 4.5 18 10.8 14.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 14.2 10.4 11.5
US
Merck & Co Inc
NYSE:MRK
216.6B USD 3.4 13.2 8.5 10.1
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
146.3B USD 2.3 13.6 7.6 10.5
P/E Multiple
Earnings Growth PEG
AU
Vita Life Sciences Ltd
ASX:VLS
Average P/E: 21.8
14
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.7
49%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19
27%
0.7
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
30.2
36%
0.8
CH
Novartis AG
SIX:NOVN
18
16%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
18%
0.8
US
Merck & Co Inc
NYSE:MRK
13.2
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.6
30%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBITDA: 395.4
7.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.9
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.5
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.6
10%
11.4
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
13%
0.8
US
Merck & Co Inc
NYSE:MRK
8.5
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBIT: 1 701.8
7.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.3
33%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19
14%
1.4
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.9
23%
7.4
CH
Novartis AG
SIX:NOVN
14.4
10%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.1
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
9%
1.2

See Also

Summary
VLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
VLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VLS stock valuation using valuation multiples.
Wall Street Estimates
VLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 276,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.